<?xml version="1.0" encoding="utf-8" standalone="yes"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Radioligand Therapy on VXB US</title>
    <link>https://www.vxbus.com/tags/radioligand-therapy/</link>
    <description>Recent content in Radioligand Therapy on VXB US</description>
    <generator>Hugo -- gohugo.io</generator>
    <language>en</language>
    <copyright>© 2026 </copyright>
    <lastBuildDate>Thu, 09 Oct 2025 20:08:06 +0800</lastBuildDate><atom:link href="https://www.vxbus.com/tags/radioligand-therapy/index.xml" rel="self" type="application/rss+xml" />
    
    <item>
      <title>Sanofi’s AlphaMedix Hits Key Efficacy Goals in Phase 2 Neuroendocrine Tumor Trial</title>
      <link>https://www.vxbus.com/news/sanofis-alphamedix-hits-key-efficacy-goals-in-phase-2-neuroendocrine-tumor-trial/</link>
      <pubDate>Thu, 09 Oct 2025 20:08:06 +0800</pubDate>
      
      <guid>https://www.vxbus.com/news/sanofis-alphamedix-hits-key-efficacy-goals-in-phase-2-neuroendocrine-tumor-trial/</guid>
      <description></description>
      <media:content xmlns:media="http://search.yahoo.com/mrss/" url="https://www.vxbus.com/news/sanofis-alphamedix-hits-key-efficacy-goals-in-phase-2-neuroendocrine-tumor-trial/featured-Sanofi-AlphaMedix.png" />
    </item>
    
  </channel>
</rss>
